Johnson Investment Counsel Inc. bought a new position in shares of iRadimed Corporation (NASDAQ:IRMD - Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 25,655 shares of the medical equipment provider's stock, valued at approximately $1,534,000. Johnson Investment Counsel Inc. owned 0.20% of iRadimed as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Jump Financial LLC raised its position in shares of iRadimed by 4.9% during the first quarter. Jump Financial LLC now owns 4,300 shares of the medical equipment provider's stock worth $226,000 after purchasing an additional 200 shares during the period. First Horizon Advisors Inc. raised its position in shares of iRadimed by 78.7% during the first quarter. First Horizon Advisors Inc. now owns 513 shares of the medical equipment provider's stock worth $27,000 after purchasing an additional 226 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of iRadimed by 5.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider's stock worth $252,000 after purchasing an additional 234 shares during the period. Martingale Asset Management L P raised its position in shares of iRadimed by 2.4% during the first quarter. Martingale Asset Management L P now owns 12,831 shares of the medical equipment provider's stock worth $673,000 after purchasing an additional 300 shares during the period. Finally, State of Wyoming raised its position in shares of iRadimed by 11.3% during the first quarter. State of Wyoming now owns 3,013 shares of the medical equipment provider's stock worth $158,000 after purchasing an additional 307 shares during the period. 92.34% of the stock is owned by institutional investors and hedge funds.
iRadimed Trading Up 1.0%
NASDAQ:IRMD opened at $72.41 on Tuesday. The firm has a market capitalization of $921.06 million, a price-to-earnings ratio of 44.70 and a beta of 1.02. iRadimed Corporation has a 1-year low of $46.86 and a 1-year high of $78.38. The business's fifty day moving average price is $71.48 and its 200 day moving average price is $61.30.
iRadimed Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Thursday, August 28th. Investors of record on Monday, August 18th were given a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend was Monday, August 18th. iRadimed's payout ratio is presently 41.98%.
Insider Buying and Selling at iRadimed
In related news, Director Monty K. Allen sold 1,102 shares of the company's stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $69.10, for a total transaction of $76,148.20. Following the transaction, the director directly owned 19,898 shares of the company's stock, valued at approximately $1,374,951.80. The trade was a 5.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Roger E. Susi sold 5,000 shares of the business's stock in a transaction dated Monday, October 6th. The shares were sold at an average price of $71.72, for a total value of $358,600.00. Following the completion of the transaction, the chief executive officer owned 2,342,500 shares in the company, valued at $168,004,100. This trade represents a 0.21% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 21,102 shares of company stock worth $1,498,348 over the last three months. 36.80% of the stock is owned by insiders.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reaffirmed a "buy (b-)" rating on shares of iRadimed in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $72.00.
Get Our Latest Analysis on iRadimed
iRadimed Profile
(
Free Report)
IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.
Featured Articles
Want to see what other hedge funds are holding IRMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iRadimed Corporation (NASDAQ:IRMD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider iRadimed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iRadimed wasn't on the list.
While iRadimed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.